Host defense peptides: General overview and an update on their activity against Chlamydia spp.

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 11, 2013, Pages 1215-1224

  Di Francesco, Antonietta ^a   Favaroni, Alison ^a   Donati, Manuela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

antibiotic resistance; Chlamydia spp.; Chlamydia trachomatis; HDP; host defense peptides; therapy

Indexed keywords

ALPHA DEFENSIN; ANTIBIOTIC AGENT; BETA DEFENSIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CECROPIN; DEFENSIN; DOXYCYCLINE; HOST DEFENSE PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; DRUG EFFICACY; HUMAN; NONHUMAN; REVIEW; SEROTYPE; TET GENE;

ANTI-BACTERIAL AGENTS; CATHELICIDINS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DEFENSINS; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; TETRACYCLINE;

EID: 84888318699     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.841450     Document Type: Review

References (107)

1. Andersen AA, Rogers DG. Resistance to tetracycline and sulphadiazine in swine C trachomatis isolates. International Chlamydia Symposium. NE, USA, 313-316 March 1998
2. Dugan J, Rockey DD, Jones L, Andersen AA. Tetracycline resistance in Chlamydia suis mediated by genomic islands inserted into the chlamydial inv-like gene. Antimicrob. Agents Chemother. 48, 3989-3995 (2004
3. Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol. 1427-1442 (2010
4. Di Francesco A, Donati M, Rossi M et al. Tetracycline- resistant Chlamydia suis isolates in Italy. Vet. Rec. 163(8), 251-252 (2008
5. Borel N, Regenscheit N, Di Francesco A et al. Selection for tetracycline-resistant Chlamydia suis in treated pigs. Vet. Microbiol. 156, 143-146 (2012
6. Schautteet K, De Clercq E, Miry C et al. Tetracycline-resistant Chlamydia suis in cases of reproductive failure on Belgian, Cypriote and Israeli pig production farms. J. Med. Microbiol. 62, 331-334 (2013
7. Jones RB, Van der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J. Infect. Dis. 162, 1309-1315 (1990
8. Lefevre JC, Lepargneur JP, Guion D, Bei S. Tetracycline-resistant Chlamydia trachomatis in Toulouse, France. Pathol. Biol. 45(5), 376-378 (1997
9. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. 181, 1421-1427 (2000
10. Wang SA, Papp JR, Stamm WE, Peeling RW, Martin DH, Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: A meeting report. J. Infect. Dis. 191(6), 917-923 (2005
11. Suchland RJ, Sandoz KM, Jeffrey BM, Stamm WE, Rockey DD. Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. Antimicrob. Agents Chemother. 53, 4604-4611 (2009
12. Mookherjee N, Hancock RE. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. 64(7-8), 922-933 (2007
13. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415(6870), 389-395 (2002
14. Brogden KA, Ackermann M, McCray PB Jr, Tack BF. Antimicrobial peptides in animals and their role in host defences. Int. J. Antimicrob. Agents 22(5), 465-478 (2003
15. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55(1), 27-55 (2003
16. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: Premises and promises. Int. J. Antimicrob. Agents 24(6), 536-547 (2004
17. Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol. 7(2), 179-196 (2005
18. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19(3), 491-511 (2006
19. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24(12), 1551-1557 (2006
20. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6(6), 447-456 (2006
21. Lai Y, Gallo RL. AMPed up immunity: How antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 30(3), 131-141 (2009
22. Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Terán LM. Antimicrobial peptides: General overview and clinical implications in human health and diseases. Clin. Immunol. 135, 1-11 (2010
23. Wiesner J, Vilcinskas A. Antimicrobial peptides: The ancient arm of the human immune system. Virulence 1(5), 440-464 (2010
24. Steinstraesser H, Kraneburg U, Jacobsen F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216, 322-333 (2011
25. Kósciuczuk EM, Lisowski P, Jarczak J et al. Cathelicidins: Family of antimicrobial peptides: A review. Mol. Bio. Rep. 39, 10957-10970 (2012
26. Lehrer RI, Lu W. a-Defensins in human innate immunity. Immunol. Rev. 245(1), 84-112 (2012
27. Ganz T. Defensins and other antimicrobial peptides: A historical perspective and an update. Comb. Chem. High Throughput Screen. 8(3), 209-217 (2005
28. Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir. Res. 1(3), 141-150 (2000
29. Wilmes M, Cammue BP, Sahl HG, Thevissen K. Antibiotic activities of host defense peptides: More to it than lipid bilayer perturbation. Nat. Prod. Rep. 28(8), 1350-1358 (2011
30. Tollin M, Bergman P, Svenberg T, Jornvall H, Gudmundsson GH, Agerberth B. Antimicrobial peptides in the first line defence of human colon mucosa. Peptides 24(4), 523-305 (2003
31. Bulet P, Stocklin R, Menin L. Anti-microbial peptides: From invertebrates to vertebrates. Immunol. Rev. 198, 169-184 (2004
32. Zanetti M, Gennaro R, Romeo D. The cathelicidin family of antimicrobial peptide precursors: A component of the oxygen-independent defense mechanisms of neutrophils. Ann. N.Y. Acad. Sci. 832, 147-162 (1997
33. Ganz T, Selsted ME, Szklarek D et al. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest. 76(4), 1427-1435 (1985
34. Pinheiro da Silva F, Machado MC. Antimicrobial peptides: Clinical relevance and therapeutic implications. Peptides 36, 308-314 (2012
35. Ménard S, Förster V, Lotz M et al. Developmental switch of intestinal antimicrobial peptide expression. J. Exp. Med. 205(1), 183-193 (2008
36. Selsted ME, Szklarek D, Lehrer RI. Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes. Infect. Immun. 45(1), 150-154 (1984
37. Zanetti M, Del Sal G, Storici P, Schneider C, Romeo D. The cDNA of the neutrophil antibiotic Bac5 predicts a pro-sequence homologous to a cysteine proteinase inhibitor that is common to other neutrophil antibiotics. J. Biol. Chem. 268(1), 522-526 (1993
38. Lehrer RI. Primate defensins. Nat. Rev. Microbiol. 2(9), 727-738 (2004
39. Tang YQ, Yuan J, Osapay G et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 286(5439), 498-502 (1999
40. Ganz T, Lehrer RI. Antimicrobial peptides of leukocytes. Curr. Opin. Hematol. 4(1), 53-58 (1997
41. Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J. Biol. Chem. 267(32), 23216-23225 (1992
42. Quayle AJ, Porter EM, Nussbaum AA et al. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am. J. Pathol. 152(5), 1247-1258 (1998
43. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3(9), 710-720 (2003
44. Duits LA, Ravensbergen B, Rademaker M, Hiemstra PS, Nibbering PH. Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 106(4), 517-525 (2002
45. Zanetti M, Gennaro R, Romeo D. Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374, 1-5 (1995
46. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75(1), 39-48 (2004
47. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118(4), 509-519 (2006
48. De Smet K, Contreras R. Human antimicrobial peptides: Defensins, cathelicidins and histatins. Biotechnol. Lett. 27, 1337-1347 (2005
49. Boman HG. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 13, 61-92 (1995
50. Hancock RE, Lehrer R. Cationic peptides: A new source of antibiotics. Trends Biotechnol. 16(2), 82-88 (1998
51. Cederlund A, Gudmundsson GH, Agerberth B. Antimicrobial peptides important in innate immunity. FEBS J. 278, 3942-3951 (2011
52. Brogden KA. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3(3), 238-250 (2005
53. Ehrenstein G, Lecar H. Electrically gated ionic channels in lipid bilayers. Q. Rev. Biophys. 10(1), 1-34 (1977
54. Pouny Y, Rapaport D, Mor A, Nicolas P, Shai Y. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 31(49), 12416-12423 (1992
55. Matsuzaki K, Murase O, Fujii N, Miyajima K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 35, 11361-11368 (1996
56. Nguyen EK, Nemerow GR, Smith JG. Direct evidence from single-cell analysis that human {alpha}-defensins block adenovirus uncoating to neutralize infection. J. Virol. 84(8), 4041-4049 (2010
57. Buck CB, Day PM, Thompson CD et al. Human alpha-defensins block papillomavirus infection. Proc. Natl. Acad. Sci. U.S.A. 103(5), 1516-1521 (2006
58. Boman HG. Antibacterial peptides: Basic facts and emerging concepts. J. Intern. Med. 254(3), 197-215 (2003
59. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273(6), 3718-3724 (1998
60. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77(4), 451-459 (2005
61. Boman HG, Agerberth B, Boman A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 61(7), 2978-2984 (1993
62. Kragol G, Lovas S, Varadi G, Condie BA, Hoffmann R, Otvos L Jr The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 40(10), 3016-3026 (2001
63. Yount NY, Yeaman MR. Peptide antimicrobials: Cell wall as a bacterial target. Ann. N.Y. Acad. Sci. 1277, 127-138 (2013
64. Schneider T, Kruse T, Wimmer R et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328(5982), 1168-1172 (2010
65. Sass V, Schneider T, Wilmes M et al. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect. Immun. 78(6), 2793-2800 (2010
66. Hancock RE. Peptide antibiotics. Lancet 349(9049), 418-422 (1997
67. Thevissen K, Warnecke DC, François IE et al. Defensins from insects and plants interact with fungal glucosylceramides. J. Biol. Chem. 279(6), 3900-3905 (2004
68. Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R. Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr. Pharm. Des. 8(9), 779-793 (2002
69. Benincasa M, Scocchi M, Podda E, Skerlavaj B, Dolzani L, Gennaro R. Antimicrobial activity of Bac7 fragments against drug-resistant clinical isolates. Peptides 25(12), 2055-2061 (2004
70. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. 84(6), 2017-2020 (1989
71. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174(10), 6257-6265 (2005
72. Niyonsaba F, Iwabuchi K, Someya A et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106(1), 20-26 (2002
73. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release.J. Immunol. 172(8), 4987-4994 (2004
74. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human bdefensins- 1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells. Eur. J. Immunol. 31, 1066-1075 (2001
75. Davidson DJ, Currie AJ, Reid GS et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172(2), 1146-1156 (2004
76. Kin NW, Chen Y, Stefanov EK, Gallo RL, Kearney JF. Cathelin-related antimicrobial peptide differentially regulates T- and B-cell function. Eur. J. Immunol. 41(10), 3006-3016 (2011
77. Choi K-Y, Mookherjee N. Multiple immune-modulatory functions of cathelicidin host defense peptides. Front. Immunol. 3(149), 1-4 (2012
78. Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J. Biol. Chem. 281(3), 1636-1643 (2006
79. Niyonsaba F, Ushio H, Nakano N et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Invest. Dermatol. 127(3), 594-604 (2007
80. Koczulla R, Von Degenfeld G, Kupatt C et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111(11), 1665-1672 (2003
81. Dorschner RA, Pestonjamasp VK, Tamakuwala S et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 117(1), 91-97 (2001
82. Heilborn JD, Nilsson MF, Kratz G et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120(3), 379-389 (2003
83. Steinstraesser L, Koehler T, Jacobsen F et al. Host defense peptides in wound healing. Mol. Med. 14(7-8), 528-537 (2008
84. Coffelt SB, Waterman RS, Florez L et al. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int. J. Cancer 122(5), 1030-1039 (2008
85. Bullard RS, Gibson W, Bose SK et al. Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer. Mol. Immunol. 45(3), 839-848 (2008
86. Büchau AS, Morizane S, Trawbridge J et al. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J. Immunol. 184(1), 369-378 (2010
87. Islam D, Bandholtz L, Nilsson J et al. Down regulation of bactericidal peptides in enteric infections: A novel immune escape mechanism with bacterial DNA as a potential regulator. Nat. Med. 7(2), 180-185 (2001
88. Ulvatne H, Haukland HH, Samuelsen Ø, Kramer M, Vorland LH. Proteases in Escherichia coli and Staphylococcus aureus confer reduced susceptibility to lactoferricin B. J. Antimicrob. Chemother. 50(4), 461-467 (2002
89. Sieprawska-Lupa M, Mydel P, Krawczyk K et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureusderived proteinases. Antimicrob. Agents Chemother. 48(12), 4673-4679 (2004
90. Lai Y, Villaruz AE, Li M, Cha DJ, Sturdevant DE, Otto M. The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in staphylococci. Mol. Microbiol. 63(2), 497-506 (2007
91. Gunn JS, Ryan SS, Van Velkinburgh JC, Ernst RK, Miller SI. Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium. Infect. Immun. 68(11), 6139-6146 (2000
92. Peschel A, Jack RW, Otto M et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med. 193(9), 1067-1076 (2001
93. Herasimenka Y, Benincasa M, Mattiuzzo M, Cescutti P, Gennaro R, Rizzo R. Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. Peptides 26(7), 1127-1132 (2005
94. Benincasa M, Mattiuzzo M, Herasimenka Y, Cescutti P, Rizzo R, Gennaro R. Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens. J. Pept. Sci. 15(9), 595-600 (2009
95. Yasin B, Harwig SSL, Lehrer RI, Wagar EA. Susceptibility of Chlamydia trachomatis to protegrins and defensins. Infect. Immun. 64 (3), 709-713 (1996
96. Kokryakov VN, Harwig SS, Panyutich EA et al. Protegrins: Leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett. 327(2), 231-236 (1993
97. Yasin B, Lehrer RI, Harwig SSL, Wagar EA. Protegrins: Structural requirements for inactivating elementary bodies of Chlamydia trachomatis. Infect. Immun. 64(11), 4863-4866 (1996
98. Chong-Cerrillo C, Selsted ME, Peterson EM, de la Maza LM. Susceptibility of human and murine Chlamydia trachomatis serovars to granulocyte- and epithelium derived antimicrobial peptides. J. Peptide Res. 61, 237-242 (2003
99. Yasin B, Pang M, Lehrer RI, Wagar EA. Activity of Novispirin G-10, a novel antimicrobial peptide against Chlamydia trachomatis and vaginosis-associated bacteria. Exp. Mol. Pathol. 74(2), 190-195 (2003
100. Yasin B, Pang M, Wagar EA. A cumulative experience examining the effect of natural and synthetic antimicrobial peptides vs. Chlamydia trachomatis. J. Pept. Res. 64(2), 65-71 (2004
101. Donati M, Di Francesco A, Gennaro R et al. Increasing effect of high dose of PG-1 peptide on the infectivity of Chlamydophila abortus. FEMS Immunol. Med.Microbiol. 59, 221-222 (2010
102. Donati M, Di Francesco A, Gennaro R et al. Sensitivity of Chlamydia suis to cathelicidin peptides. Vet. Microbiol. 123, 269-273 (2007
103. Park N, Yamanaka K, Tran D et al. The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of Chlamydia trachomatis. J. Antimicrob. Chemother. 63(1), 115-123 (2009
104. Ballweber LM, Jaynes JE, Stamm WE, Lampe MF. In vitro microbicidal activities of cecropin peptides D2A21 and D4E1 and gel formulations containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob. Agents Chemother. 46(1), 34-41 (2002
105. Skinner MC, Kiselev AO, Isaacs CE, Mietzner TA, Montelaro RC, Lampe MF. Evaluation of WLBU2 peptide and 3-Ooctyl- sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis. Antimicrob. Agents Chemother. 54(2), 62-7236 (2010
106. Donati M, Di Francesco A, D́Antuono A et al. Chlamydia trachomatis serovar distribution and other concurrent sexually transmitted infections in heterosexual men with urethritis in Italy. Eur. J. Clin. Microbiol. Infect. Dis. 28(5), 523-526 (2009
107. Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr. Opin. Pharmacol. 6(5), 468-472 (2006